The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Infliximab for hidradenitis suppurativa
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic disease characterized by significant morbidity. Current medical therapies are only minimally effective at treating the disease. Infliximab is a chimeric monoclonal antibody with high affinity for tumour necrosis factor (TNF)-alpha. TNF-alpha is known to induce proinflammatory cytokines and may play an important role in the therapy of a number of disparate inflammatory disorders. Infliximab has shown promise for the therapy of rheumatoid arthritis and psoriasis. OBJECTIVES: Retrospectively to evaluate the effectiveness of infliximab for the treatment of HS. METHODS: A retrospective chart review was performed for patients who received infliximab at the University of Miami Department of Dermatology. Patients were contacted and asked retrospectively to rate their disease activity immediately prior to and after therapy. RESULTS: Patients' self-reported disease activity scores were significantly decreased (P = 0.0001, paired t-test) following infliximab infusion. This correlated with physician-observed clinical improvement. CONCLUSIONS: Infliximab is a promising agent for the treatment of HS. These initial results suggest that infliximab is associated with objective and subjective improvement in HS. Further controlled studies of the efficacy of infliximab and its effect on the course of the disease are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Cited by
Hidradenitis suppurativa: A comprehensive review
Alikhan, A., Lynch, P. J., & Eisen, D. B. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.11.911 · Cited by 705
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
Sartorius, K., Emtestam, L., Jemec, G. B. E., & Lapins, J. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09198.x · Cited by 525
Obesity and the skin: Skin physiology and skin manifestations of obesity
Yosipovitch, G., DeVore, A., & Dawn, A. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.12.004 · Cited by 524
Grant, A., Gonzalez, T., Montgomery, M. O., Cardenas, V., & Kerdel, F. A. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.06.050 · Cited by 419
Self-citationRevuz, J. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03356.x · Cited by 336
Metadata
- Authors
- Sullivan, T. P., Welsh, E., Kerdel, F. A., Burdick, A. E., & Kirsner, R. S.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11
- Volume
- 149
- Issue
- 5
- Pages
- 1046-1049
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2128583237
- Cited by
- 158
- References
- 1
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Infliximab for hidradenitis suppurativa. https://app.cochat.ai/papers/10.1111/j.1365-2133.2003.05663.x
- The paper
- Sullivan, T. P., Welsh, E., Kerdel, F. A., Burdick, A. E., & Kirsner, R. S. (2003). Infliximab for hidradenitis suppurativa. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2003.05663.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.